Which TikTok policies actually apply
Two live pages, not three. The first is TikTok's Healthcare and Pharmaceuticals advertising policy, whose date line reads “Last updated: September 2026”. Its Policy section states that “Some healthcare-related content cannot be advertised at all, while others can be advertised with restrictions in place,” and the principle above it reads: “At TikTok, all healthcare and pharmaceutical products and services advertised on the platform must be in compliance with all applicable laws and regulations in each market.” Both checked 7 October 2026. That second sentence is the one to notice first, because it hands the answer back to your own market's regulator rather than settling it platform-wide.
The second is the Dangerous Products or Services policy, date line “Last updated: April 2025”, and the part that matters here is its Drugs section, one of four policy sections on that page. The other three cover weapons, ammunition and explosives, police or military gear and equipment, and tobacco and nicotine-related products, so a bare reference to “TikTok's dangerous products policy” reads as though a research catalog were filed next to firearms.
Now the third page. TikTok used to publish a standalone drugs and drug paraphernalia advertising policy. That URL is retired. It still returns a page, which is why stale links look alive, and the body of that page reads “Sorry! The article you are looking for no longer exists or failed to load,” checked 7 October 2026. The rule was not repealed. It moved into the Drugs section above. One more piece of plumbing if you keep your own policy notes: the older help path form of both URLs now redirects to the resources path, so cite the resources form that this page links.
What the Drugs section's examples list says
The policy sentence itself, verbatim from the Drugs section: “We do not allow ad content and landing pages to display, promote, sell, solicit, or provide access to illegal drugs, controlled drugs, prescription drug abuse, recreational drugs, drug paraphernalia, accessories, supplies, or their use,” checked 7 October 2026. Read what that sentence covers twice. It covers “ad content and landing pages”, which means the review reaches the page you send traffic to, not only the video and the caption you uploaded.
Under it, the same section lists examples of what is not allowed. One of those items answers more operator questions than the policy sentence does: “Illegal drugs, controlled drugs, prescription drugs, and drugs for the purpose of recreation, homeopathy, enhancement, performance, and weight loss,” checked 7 October 2026. The trigger named there is a purpose, not an ingredient list. So the thing that gets an ad pulled is usually the angle. A line in the creative, or a headline on the page you send traffic to, states one of the purposes the policy names.
Two more items from that same list are worth having in front of you when a rejection makes no sense. “Unauthorized drugstores, pharmacies, or dispensaries” is about the advertiser rather than the product, and “Depiction of drug-related words, symbols, or images in visuals, audio, or any other form” covers the creative itself, which is the honest citation when the complaint seems to be about imagery or a single word rather than the offer.
The section also carries an exception, and it is narrower than it reads at a glance: “Prescription drugs may be allowed in select markets if the following requirements are met: Be approved by the regional regulating authority Do not include misleading or inaccurate claims Restrict ads to viewers aged 18 years and older.” On the live page, “select markets” carries a footnote that reads “Applicable to: Canada, United States”. Quote the footnote with the clause or leave both out, because without it the sentence reads as a general allowance, and the first requirement in it is approval by a regulator.
What the healthcare policy adds in the United States
The healthcare policy is built as market tables, and the row your market carries is the only row that governs your account. Most market tables on that page list prescription medicine as Not allowed. The United States table does not, and its prescription-medicine row reads, verbatim: “May be allowed if the following requirements are met: - Provide proof of approval and certification from appropriate local regional regulating authorities, such as the US Food and Drug Administration (FDA) - Restrict the ads to audiences aged 18 years or older,” checked 7 October 2026.
Read that as written, because it is not a door. It is a documentation requirement: proof of approval from the regulator, plus an age restriction on the audience. Nothing without that approval is covered by it, a compounded preparation is not an approved drug, and a research catalog does not become eligible by citing the row. The test is who certified the product, and the answer has to be a regulator rather than you.
The same United States table carries a row about the advertiser instead of the product: “Ads for brick-and-mortar pharmacies and online pharmacies may be allowed if the following requirement is met: - Provide proof of certification by a third-party licensing organization, such as the National Association of Boards of Pharmacy (NABP) or LegitScript, or regional equivalent,” checked 7 October 2026. That is a rule about who may advertise, and it says nothing about any product category.
One absence is worth stating plainly, because an absence gets misreported as a permission. The United States table carries rows for prescription medicine, over-the-counter medicines, medical devices, cosmetic clinics, cosmetic surgeries, medical institutions, pharmacies, condoms and lubricants, and CBD products, and no dietary supplements row, checked 7 October 2026. Other markets do have one, with local conditions attached, and those rows are about those markets. Another market's supplement row is not cover for a US advertiser. And a supplement framing is not a route for a research-use catalog. The wider version of that argument, across every platform that gates this category, is in our compliance landscape piece.
Creator posts and TikTok Shop follow different rules
Three different rule sets get collapsed into one question. Paid ads are governed by the two policies above. Organic and creator posts sit under TikTok's rules for content on the platform, which are not the advertising policies, and a post that is paid for is advertising when it comes to disclosure, whoever uploaded it. Before you brief a creator, read the FTC's guidance on endorsements, influencers and reviews, checked 7 October 2026, which collects the FTC's plain-language guidance, including “Disclosures 101 for Social Media Influencers” and “FTC's Endorsement Guides: What People Are Asking”. The claims rules do not loosen because someone else is saying them on camera.
Three things to put in the brief, in plain words. A paid post carries the disclosure inside the post itself, not in a bio and not in a comment. The claims in a creator's own words are held to the same standard as the claims in your own ad copy. Anything you would not write on the product page does not go in the brief either. And nothing in the brief invites first-person use language, body imagery or dose-like numbers, because those are the purposes the policy above names.
Boosting a post you already published, rather than uploading new ad creative, is still an ad. The two policies above apply to it in the same words, the landing page you attach is still in scope, and an organic post clearing the platform rules is not a review decision about an ad. Treat it as a format choice, not as a different rule set.
Selling through TikTok Shop is governed separately again, by seller terms rather than by advertising policy. We have not fetched that policy for this page, so this page will not characterise it. Read it before you build on it, and treat an approval in one lane as saying nothing about the other two.
What these two policies do not say
Neither page uses the word peptide. Not once, on either URL, checked 7 October 2026. So the sentence “TikTok bans peptides” is not in TikTok's policy, and you will not read it here. What the pages do is describe categories and purposes, and someone at TikTok decides whether your ad and its landing page fall inside them. That is the real mechanism, and it is why two brands in the same category get different answers.
Two things follow. First, treat any page that tells you TikTok explicitly permits or prohibits a named compound as unsourced until it quotes a clause. Second, keep your own record, with the wording, the URL and the date you read it, because a policy page you cannot quote is a policy page you cannot plan around. Ours is public: the policy tracker quotes the ad and email platform clauses in full, and advertising in this category covers how the restricted-product reviews work in practice.
If an ad is disapproved, start with the policy the notice names and read the clause itself, then compare it with the creative and with the headline on the page you point traffic at, because both are in scope. Neither of these two TikTok pages publishes an appeal process, so this page will not describe one: check the notice in your own account for the route it offers. For the shape of that work on another platform, our post on a disabled Meta ad account walks the cause-then-appeal order.
Email is the channel no ad reviewer gates
None of this makes paid social impossible. It does make it a channel you rent, on terms someone else writes and can rewrite. Email is the other side of that: the list is yours, and no ad review sits between a send and the person who asked to hear from you.
That is what Amino Engine is for. It is an email platform for peptide brands: 82 ready-made flows to start from, campaigns, a drag-and-drop builder, segments, forms with double opt-in built in, and revenue reporting. Mail sends from your own domain, on servers and IP addresses we run, so no outside email provider sits above your account. New senders are warmed up over 42 days. There is a WooCommerce plugin today and Shopify is next. If you are moving, you import from Klaviyo or Brevo by CSV, and unsubscribes and bounces carry over as unsubscribes and bounces. Revenue is attributed to the last email click within five days, and opens never count.
Which email platform will keep a brand in this category is its own question, and it is answered with policy wording the same way this page is: see which email platforms allow peptide brands for each clause in full, or see how the platform itself works. See pricing for plans and email volumes. The trial runs seven days, every feature included, no card to start.
This is general information, not legal advice.